“…Recent studies have shown that compounds targeting mGluR2/3 are well-tolerated, exhibit few side-effects, and demonstrate a strong potential for alleviating cognitive impairments in both animal models and human subjects with SCZ (Helton et al, 1998; Spooren et al, 2002; Swanson et al, 2005; Fell et al, 2012; Harvey and Shahid, 2012). Specifically, activation of mGluR2/3 can decrease glutamate release pre-synaptically (Schoepp et al, 1999; Cartmell and Schoepp, 2000; Moghaddam, 2004), and simultaneously potentiate NMDAR function post-synaptically (Tyszkiewicz et al, 2004; Xi et al, 2011; Cheng et al, 2013; Trepanier et al, 2013; Wang et al, 2013; Li et al, 2015a; Li et al, 2015b; Engel et al, 2016). …”